Search Results - Drugs

Transporters in drug delivery

Table of Contents: “…Contents: Biotransporters in drug delivery -- Classification of transporters -- P-glycoprotein transporters -- Transporters for cancer therapy -- Solute carrier transporters -- Facilitative glucose transporters -- The substrates and inhibitors of different transporters -- Effect of transporters in drug delivery -- Pharmacological applications.…”
Get full text
Series

Transporters in drug delivery

Table of Contents: “…Contents: Biotransporters in drug delivery -- Classification of transporters -- P-glycoprotein transporters -- Transporters for cancer therapy -- Solute carrier transporters -- Facilitative glucose transporters -- The substrates and inhibitors of different transporters -- Effect of transporters in drug delivery -- Pharmacological applications.…”
Get full text
Series

Development of a cancer drug

Table of Contents: “…Contents: Requirements for drug approval in the U.S. -- Legal evolution of drug approval -- The FDA and oncology drugs -- Clinical trial phases -- The effectiveness requirement -- Traditional and new approaches to trial design -- Types of controls -- Targeted therapies -- Companion diagnostics -- Endpoints for oncology trials -- Types of drug approval -- New drug application (NDA) -- Biomarkers -- FDA reviews and approvals.…”
Get full text
Series

Drug delivery for cancer therapeutics

Table of Contents: “…Contents: Cancer therapeutics -- Drug delivery mechanisms -- Drug development -- Liposomes -- Nanoparticles -- Nanotechnology -- Nanotoxicology -- Niosomes -- Dendrimers -- Micelles -- Routes of drug delivery.…”
Get full text
Series

Need for drug delivery systems part 2 /

Table of Contents: “…Contents: The need for delivery system in oncology -- Lipid-based nanotechnologies: a clinical reality -- Improving biodistribution and pharmacokinetics and safety -- Improving therapeutic outcome upon increasing drug release at target organ -- Targeting tumor microenvironment at two different cell levels -- Improving formulation.…”
Get full text
Series

Need for drug delivery systems part 2 /

Table of Contents: “…Contents: The need for delivery system in oncology -- Lipid-based nanotechnologies: a clinical reality -- Improving biodistribution and pharmacokinetics and safety -- Improving therapeutic outcome upon increasing drug release at target organ -- Targeting tumor microenvironment at two different cell levels -- Improving formulation.…”
Get full text
Series

Drug delivery for cancer therapeutics

Table of Contents: “…Contents: Cancer therapeutics -- Drug delivery mechanisms -- Drug development -- Liposomes -- Nanoparticles -- Nanotechnology -- Nanotoxicology -- Niosomes -- Dendrimers -- Micelles -- Routes of drug delivery.…”
Get full text
Series

Development of a cancer drug

Table of Contents: “…Contents: Requirements for drug approval in the U.S. -- Legal evolution of drug approval -- The FDA and oncology drugs -- Clinical trial phases -- The effectiveness requirement -- Traditional and new approaches to trial design -- Types of controls -- Targeted therapies -- Companion diagnostics -- Endpoints for oncology trials -- Types of drug approval -- New drug application (NDA) -- Biomarkers -- FDA reviews and approvals.…”
Get full text
Series

The mTOR kinase as a target for anti-cancer drugs

Subjects: “…Neoplasms drug therapy.…”
Get full text
Series

The mTOR kinase as a target for anti-cancer drugs

Subjects: “…Neoplasms drug therapy. 108882…”
Get full text
Series

The mTOR kinase as a target for anti-cancer drugs

Subjects: “…Neoplasms drug therapy. 108882…”
Get full text
Series

Drug metabolizing enzymes in cancer therapeutics

Table of Contents: “…Contents: Drug metabolism -- Classification of drug metabolizing enzymes (DMEs) -- Clinical significance of DMEs in cancer therapeutics -- Drug delivery -- Drug resistance -- Interindividual variability and precision oncology.…”
Get full text
Series

Changing paradigms in anticancer drug development inhibiting angiogenesis in colorectal cancer /

Table of Contents: “…Contents: Targeted therapy for cancer -- Angiogenesis is involved throughout tumour formation, growth and metastasis -- VEGF: molecular characteristics -- VEGF and other signals promote the angiogenic switch in tumours -- Tumour vasculature is abnormal -- VEGF produces immature tortuous vessels dependent on VEGF for survival -- Other features make VEGF an attractive target for anticancer therapy -- RhuMAb VEGF (bevacizumab/Avastin®) -- Significant reduction in microvasculature -- Anti-VEGF antibody improves drug delivery -- Avastin: an anti-VEGF agent for cancer therapy -- Use of Avastin with oxaliplatin-based therapy -- Addition of Avastin to oxaliplatin-based chemotherapy improved best confirmed response -- Study schema and organization.…”
Get full text
Series

Drug metabolizing enzymes in cancer therapeutics

Table of Contents: “…Contents: Drug metabolism -- Classification of drug metabolizing enzymes (DMEs) -- Clinical significance of DMEs in cancer therapeutics -- Drug delivery -- Drug resistance -- Interindividual variability and precision oncology.…”
Get full text
Series

Changing paradigms in anticancer drug development inhibiting angiogenesis in colorectal cancer /

Table of Contents: “…Contents: Targeted therapy for cancer -- Angiogenesis is involved throughout tumour formation, growth and metastasis -- VEGF: molecular characteristics -- VEGF and other signals promote the angiogenic switch in tumours -- Tumour vasculature is abnormal -- VEGF produces immature tortuous vessels dependent on VEGF for survival -- Other features make VEGF an attractive target for anticancer therapy -- RhuMAb VEGF (bevacizumab/Avastin®) -- Significant reduction in microvasculature -- Anti-VEGF antibody improves drug delivery -- Avastin: an anti-VEGF agent for cancer therapy -- Use of Avastin with oxaliplatin-based therapy -- Addition of Avastin to oxaliplatin-based chemotherapy improved best confirmed response -- Study schema and organization.…”
Get full text
Series

Changing paradigms in anticancer drug development inhibiting angiogenesis in colorectal cancer /

Table of Contents: “…Contents: Targeted therapy for cancer -- Angiogenesis is involved throughout tumour formation, growth and metastasis -- VEGF: molecular characteristics -- VEGF and other signals promote the angiogenic switch in tumours -- Tumour vasculature is abnormal -- VEGF produces immature tortuous vessels dependent on VEGF for survival -- Other features make VEGF an attractive target for anticancer therapy -- RhuMAb VEGF (bevacizumab/Avastin®) -- Significant reduction in microvasculature -- Anti-VEGF antibody improves drug delivery -- Avastin: an anti-VEGF agent for cancer therapy -- Use of Avastin with oxaliplatin-based therapy -- Addition of Avastin to oxaliplatin-based chemotherapy improved best confirmed response -- Study schema and organization.…”
Get full text
Series

Drug metabolizing enzymes in cancer therapeutics

Table of Contents: “…Contents: Drug metabolism -- Classification of drug metabolizing enzymes (DMEs) -- Clinical significance of DMEs in cancer therapeutics -- Drug delivery -- Drug resistance -- Interindividual variability and precision oncology.…”
Get full text
Series

Pain and symptom control in palliative care new ways to think about old drugs /

Subjects: “…Neoplasms drug therapy.…”
Get full text
Series

Pain and symptom control in palliative care new ways to think about old drugs /

Subjects: “…Neoplasms drug therapy. 113204…”
Get full text
Series

Pain and symptom control in palliative care new ways to think about old drugs /

Subjects: “…Neoplasms drug therapy. 113204…”
Get full text
Series